Anti-adrenomedullin (ADM) antibody or Anti-ADM antibody fragment or Anti-ADM non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
Patent Information
- Application Number
- MX2019007107
- Authority / Receiving Office
- MX · MX
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-10-18
- Filing Date
- 2019-06-14
- Publication Date
- 2026-02-25
- Estimated Expiration
- 2037-12-18
AI Technical Summary
Current treatments for conditions like congestive heart failure and sepsis often lead to kidney damage due to the use of diuretics, and there is a lack of accurate diagnostic markers for congestion, leading to inadequate decongestion and increased hospital readmissions.
Administration of an anti-Adrenomedullin (ADM) antibody or fragment that binds to ADM without Ig, which stabilizes plasma ADM levels, reducing vascular permeability and enhancing endothelial integrity, combined with a diagnostic method using Pro-Adrenomedullin levels to guide therapy.
This approach protects the kidneys from diuretic-induced harm and effectively reduces congestion by stabilizing ADM levels, improving vascular integrity, and providing a reliable marker for decongestion, thereby reducing hospital readmissions.